Washington Politics and Genetic Engineering Research: When Worlds Collide
- 1 January 1996
- journal article
- Published by Mary Ann Liebert Inc in Human Gene Therapy
- Vol. 7 (1) , 97-108
- https://doi.org/10.1089/hum.1996.7.1-97
Abstract
In earlier research, I developed a notion of "biopolitics" to help explain, first, the recombinant DNA debate of the 1970-1980s, and, second, the human gene transfer-therapy debate of the 1980-1990s. Drawing upon results gleaned from two recent meetings of high moment in the nation's capital, I expand upon the theoretical and empirical parameters of the biopolitical argument to elucidate the clash of policy preferences arising from two new areas of genetic experimentation: (i) human embryo research and (ii) the creation of commercially viable therapeutics to combat disease. I show the manner in which members of the biological science community and their policy allies are forced to cope with the realities of the "Washington political game," and why it is necessary for them to develop a sophisticated sense of what that "game" is.Keywords
This publication has 10 references indexed in Scilit:
- FDA Reform: Arguments on Both SidesHuman Gene Therapy, 1995
- Clinton Rules Out Some StudiesScience, 1994
- Rules on Embryo Research Due OutScience, 1994
- The BioEast MeetingHuman Gene Therapy, 1994
- Bioethics, Public Policy, and Political SciencePolitics and the Life Sciences, 1994
- Musings on the Struggle—Part III: The October 3 RAC MeetingHuman Gene Therapy, 1993
- Finding a Forum for Bioethics in U.S. Public PolicyPolitics and the Life Sciences, 1993
- Human Gene Therapy: A Biopolitical Overview and AnalysisHuman Gene Therapy, 1993
- ScienceScopeScience, 1992
- Chess algorithms of supreme court decision making: A bioconstitutional politics analysisPolitical Behavior, 1989